Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Key Takeaways A new blood test can diagnose Alzheimer’s disease and track its progressionThe test looks for tau proteins that ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

The ratio of two proteins that help brain cells communicate with each other may be a stronger indicator for cognitive ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – ...

Researchers have developed a new blood test that can detect Alzheimer's disease and monitor its progression by measuring ...

Trontinemab is currently being studied in the Phase Ib/IIa Brainshuttle AD study assessing the safety, tolerability, ...

Researchers have developed a blood test that detects Alzheimer’s disease and stages its progression, offering an alternative ...

Those findings were integrated with data collected from the participants on cerebrospinal fluid and brain-scan biomarkers of amyloid- β and tau protein, cognitive function, age, sex and Alzheimer ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.